Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?

Link to article at PubMed

Related Articles

Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?

Expert Opin Pharmacother. 2019 Mar 28;:1-4

Authors: Raschi E, Poluzzi E, Marchesini G, De Ponti F

INTRODUCTION: Individuals with type 2 diabetes mellitus (T2DM) have increased cardiovascular risk with regulatory agencies requiring cardiovascular outcome trials (CVOTs) for the approval of new antidiabetic drugs. Areas covered: In this paper, the authors critically discuss the background, trial design, results and implications of a recent CVOT [NCT01730534; DECLARE-TIMI 58 study], which demonstrated that dapagliflozin was non-inferior to placebo in terms of major adverse cardiovascular events, and superior for the occurrence of hospitalization for heart failure (HF) and composite renal endpoints, thus confirming the cardiovascular benefit of sodium-glucose co-transporter-2 (SGLT2) inhibitors. No statistically-significant effects were found for amputations, fractures, and stroke (debated safety issues having emerged in previous CVOTs). Expert opinion: DECLARE-TIMI 58 is the longest (4.2 years of follow up), largest (>17,000 participants) and most inclusive (only 41% of individuals with established atherosclerotic cardiovascular disease) CVOT raising the debate towards SGLT2 inhibitor therapy in primary prevention and the potential use of these drugs also in patients with HF without T2DM and other subpopulations.

PMID: 30920851 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *